We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
<sup>177</sup>Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer.
- Authors
Stewart, Patricia
- Abstract
The article focuses on approval of cabazitaxel (Jevtana) as third-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC) after treatment with docetaxel and an androgen receptor inhibitor. Topics discussed include information on 177Lu-PSMA-617 as an alternative to cabazitaxel; role of 177Lu-PSMA-617 to improve the domains of social functioning, fatigue, insomnia, and diarrhea; and improvement in deterioration-free survival.
- Subjects
CASTRATION-resistant prostate cancer; CABAZITAXEL
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 4, p15
- ISSN
2164-4403
- Publication type
Article